Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in di
- PDF / 1,140,126 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 114 Downloads / 185 Views
ORIGINAL INVESTIGATION
Cardiovascular Diabetology Open Access
Association between omentin‑1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study Federico Biscetti1,2,3,9* , Elisabetta Nardella2, Maria Margherita Rando2, Andrea Leonardo Cecchini2, Flavia Angelini3, Alessandro Cina4, Roberto Iezzi4, Marco Filipponi5, Angelo Santoliquido1,6,7, Dario Pitocco1,6,8, Raffaele Landolfi1,2,6 and Andrea Flex1,2,3,6
Abstract Background: Cardiovascular complications represent the major cause of morbidity and mortality of type 2 diabetes mellitus (T2DM) patients. In particular, peripheral artery disease (PAD) represents a frequent T2DM vascular complication and a risk factor for the development of major adverse cardiovascular events (MACE). Among adipokines, omentin-1 serum levels are reduced in T2DM patients with PAD and are inversely related to disease severity. Objective: To study the relationship between omentin-1 levels, at baseline, with outcomes after endovascular procedures in T2DM patients with PAD and chronic limb-threatening ischemia (CLTI). Research design and methods: We enrolled for our prospective non-randomized study, 207 T2DM patients with PAD and CLTI, requiring revascularization. Omentin-1 serum levels were collected before revascularization and patients incidence outcomes were evaluated at 1, 3, 6 and 12 months. Results: Omentin-1 was reduced in patients with more severe disease (27.24 ± 4.83 vs 30.82 ± 5.48 ng/mL, p
Data Loading...
